Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Critical Therapeutics is cutting 63 positions, more than half its workforce, as it focuses on commercializing the controlled-release form of zileuton for the treatment of asthma. Among the eliminated jobs are 20 in R&D and 32 in the sales and marketing of standard zileuton, sold as Zyflo. Meanwhile, QLT is eliminating about 80 jobs in response to a continued decline in sales of Visudyne, its treatment for age-related macular degeneration. QLT employed 438 people as of March 1.
This article has been sent to the following recipient: